Home         Forums  

Go Back   Marrowforums > Bone Marrow Failure Diseases > News and Events
Register FAQ Search Today's Posts Mark Forums Read

News and Events News related to bone marrow failure diseases

Reply
 
Thread Tools Search this Thread
  #1  
Old Tue May 21, 2013, 02:50 PM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Thumbs up Abstracts from the EHA Conference

Hi All,
Now the abstracts from the European Hematology Conference 2013 in Stockholm are available.
https://b-com.mci-group.com/EventProgramme/EHA18.aspx
Kind regards
Birgitta-A
Reply With Quote
  #2  
Old Tue May 21, 2013, 03:16 PM
Neil Cuadra Neil Cuadra is offline
Owner
 
Join Date: Jul 2006
Location: Los Angeles, California
Posts: 2,553
One abstract in particular caught my eye:

EHA18ABSSUB-3848

MULTICENTER STUDY EVALUATING THE IMPACT OF HYPOMETHYLATING AGENTS AS BRIDGING THERAPY TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROMES

The authors studied the effects of azacitidine or decitabine before a transplant, to learn whether these drugs had a positive or negative effect on the subsequent transplant. They found that taking these hypomethylating agents can make engraftment take longer, which is a disadvantage. However, they also found that patients with higher blast counts had longer "event-free" survival if they took hypomethylating agents before their transplant, despite the longer time to engraftment.

As is common, the authors recommend more research, but this lends weight to the notion that it is suitable for high-risk MDS patients to take Vidaza or Dacogen even if they are going to have a transplant, and that this is less desirable for low-risk MDS patients.
Reply With Quote
  #3  
Old Wed May 22, 2013, 03:02 PM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Revlimid + EPO

Hi All,
Here is an abstract about Revlimid (lenalidomide) combined with EPO.

EHA 2013 A RANDOMISED STUDY OF LENALIDOMIDE (LEN) +/- EPO IN RBC TRANSFUSION DEPENDENT (TD) IPSS LOW AND INT-1 (LOWER RISK) MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL 5Q RESISTANT TO EPO
Andrea Toma 1,*, Sylvie Chevret 2, Olivier Kosmider 3 et al. 1Hopital Henri Mondor, Creteil, 2Hopital Saint Louis, 3Hopital Cochin, Paris, France.

Background
ESAs, the first line treatments of anemia in non del 5q lower risk MDS, yield only 40-50% responses. LEN gives RBC transfusion independence (TI) in about 25% of ESA resistant (or relapsing) TD lower risk MDS without del 5q (Raza, Blood, 2008), and a gene expression signature can predict response (Ebert, Plos Med 2008).

Aims
We randomized in this patient population LEN alone and LEN+EPO.

Methods
In this prospective multicenter open-label phase II study, lower risk MDS patients without del 5q, with TD (≥4 RBC units during the previous 8 weeks (w)) and with ESA resistance or relapse after a response were randomized between LEN alone, 10mg/d x 21 d/4 w (L arm) or LEN (same schedule) + EPO beta, 60 000 U/w (LE arm). The primary endpoint was erythroid response (HI-E, IWG 2006 criteria) after 4 treatment cycles. Secondary objectives included identification of biomarkers of response.

Results
Between July 2010 and June 2012, 132 patients (pts, 66 / arm), median age 73 (range 46-88), M/F: 88/44 were enrolled. Median TD was 6 RBC units/8w (range 2-18). IPSS was Low in 45% and Int-1 in 55% pts. Pretreatment characteristics did not differ between the 2 groups.

All but 3 pts, who withdrew consent (2L+1LE), were evaluable for response. In this ITT population, HI-E was obtained in 15 pts (23.4%) in L arm and 26 (40.0%) in LE arm (RR= 1.7, p= 0.043, chi2 test), and TI in 9 (14.1%) versus 16 (24.6%) pts (RR=1.7, p= 0.13).

In the 99 pts who completed 4 treatment cycles, 41 achieved HI-E, including 15/49 (30.6%) in L arm versus 26/50 (52.0%) in LE arm (p= 0.03), and TI in 9 (18.4%) versus 16 (32.0%) pts (RR= 1.7, p=0.12). Side effects (cytopenias and 1 DVT/arm) were similar in the 2 arms.

A 29-gene expression profile signature predicting HI-E to L or LE, different from that previously published, was identified and a polymorphism in the CRBN gene (Kosmider, submitted) was significantly associated with HI-E in the entire cohort (p=0.034).

Summary / Conclusion
LEN + EPO yielded a significantly better erythroid response than LEN alone in lower risk MDS patients with anemia resistant to ESA alone. A gene expression signature and a CRBN gene polymorphism correlated with the erythroid response.


Kind regards
Birgitta-A
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
One-day Patient Conference in San Antonio, Texas, October 8, 2016 Marrowforums News and Events 2 Mon Sep 19, 2016 02:53 PM
One-day Patient Conference in San Diego, California, September 17, 2016 Marrowforums News and Events 1 Thu Sep 15, 2016 12:49 AM
One-day Patient Conference in Cincinnati, Ohio, April 30, 2016 Marrowforums News and Events 1 Tue Apr 12, 2016 01:19 PM
One-day Patient Conference in West Palm Beach, Florida, November 6, 2016 Marrowforums News and Events 0 Sun Feb 7, 2016 10:34 PM
AA&MDSIF 2010 Patient & Family Conference Marrowforums News and Events 18 Mon Jul 19, 2010 10:47 AM


All times are GMT -4. The time now is 04:26 PM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org